Quick Facts: Therapeutic Domains

• Support for Primary Biliary Cholangitis (PBC): May help manage the progression of this chronic liver condition.
• Cholesterol Gallstones: Used to promote the gradual dissolution of specific types of gallstones.

---

Урсолив (Ursodeoxycholic Acid) is a viable therapeutic option for managing certain conditions involving the liver and bile duct system. Its primary use is in the treatment of primary biliary cholangitis (PBC), a chronic autoimmune liver disease. Regular administration may provide support in slowing the disease's progression and improving relevant biochemical markers of liver health, such as enzyme levels.

This agent is also generally used for the dissolution of gallstones that are composed mainly of cholesterol, offering an alternative when surgical intervention is not recommended or preferred. This treatment is generally appropriate for smaller, non-calcified gallstones and may require an extended period of therapy to achieve the desired effect.

The eligibility for Урсолив (Ursodeoxycholic Acid) is strictly defined by official regulatory documentation, primarily relating to the status of the patient's biliary tract, liver function, and specific comorbidities.

Eligibility Scope

Category	Status Defined by Regulatory Label
Allowed Populations	Adults with Primary Biliary Cholangitis (PBC) or X-ray radiolucent, non-calcified cholesterol gallstones. Use is also established for children aged 6–18 years with Cystic Fibrosis-associated hepatobiliary disorders [Source 1.7, 2.1].
Contraindicated Populations	Individuals with biliary tract occlusion, acute inflammation of the gallbladder or bile ducts, a non-functioning gallbladder, calcified gallstones, or a history of frequent biliary colic [Source 1.7]. Contraindication also extends to patients with active gastric/duodenal ulcers or decompensated hepatic cirrhosis [Source 1.7].

Conditional and Restricted Use

Pregnancy and Lactation: The medicine is contraindicated during pregnancy unless the necessity is essential, due to limited human data and reproductive concerns from animal studies [Source 1.7]. Women of childbearing potential must use effective contraception. Use during lactation is not recommended [Source 1.7].

Comorbidity: Patients must be monitored for abnormal liver function tests, and use is restricted in conditions that interfere with the enterohepatic circulation of bile acids, such as regional ileitis [Source 1.7, 2.4].

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Урсолив (Ursodeoxycholic Acid) based on its chemical properties and effects on bile composition.

Interaction Type	Interacting Substances/Categories	Regulatory Requirement
Reduced Efficacy of Урсолив	Bile Acid Sequestering Agents (e.g., Cholestyramine, Colestipol); Aluminum-based Antacids	Timing Separation Required: Must be taken at least 2 hours before or after the dose of Урсолив to prevent binding and reduction of absorption.
Antagonism of Therapeutic Effect	Oestrogens/Estrogens; Hormonal Oral Contraceptives; Certain Blood Cholesterol Lowering Agents (e.g., Clofibrate)	Restriction: Should not be used simultaneously for gallstone dissolution, as these agents increase cholesterol secretion, counteracting Урсолив's effect. Non-hormonal contraception is advised for women using the drug for this indication.
Altered Exposure of Co-administered Drugs	Ciclosporin; Nitrendipine; Dapsone; Ciprofloxacin	Monitoring Required: Урсолив can increase the intestinal absorption of Ciclosporin, necessitating monitoring and dose adjustment. It is also documented to reduce the plasma exposure ( AUC/ C max) of Nitrendipine and the therapeutic effect of Dapsone, and may reduce the absorption of Ciprofloxacin.

The regulatory interaction profile primarily addresses substances that interfere with bile acid absorption and those that pharmacodynamically oppose the drug's intended action of dissolving cholesterol gallstones. This framework establishes necessary timing separation for binding agents and alerts prescribers to potential adjustments needed for co-administered drugs like Ciclosporin.

Урсолив contains ursodeoxycholic acid (UDCA), a hydrophilic bile acid that becomes a major constituent of the total endogenous bile acid pool upon administration, primarily accumulating in the liver and biliary system. Its mechanism involves several distinct actions:

1. Bile Acid Pool Modulation: UDCA competitively displaces more hydrophobic and potentially cytotoxic bile acids from the enterohepatic circulation, thereby altering the overall hydrophobicity index of the circulating bile acid mixture.
2. Cholesterol Saturation Reduction: UDCA acts as an inhibitor of intestinal cholesterol absorption and a suppressor of hepatic cholesterol secretion into bile. Downstream, this action reduces the saturation of bile with cholesterol, forming less lithogenic mixed micelles.
3. Hepatocyte Cytoprotection: The molecule is an anti-apoptotic agent, acting on the mitochondrial membrane of hepatocytes and cholangiocytes. It stabilizes the membrane against disruption and inhibits the release of cytochrome C, thereby blocking the intrinsic mitochondrial pathway of apoptosis.
4. Biliary Secretion Stimulation: UDCA stimulates the biliary secretion of bile acids and bicarbonate by increasing intracellular calcium levels in cholestatic hepatocytes, which in turn stimulates the insertion and activity of apical transport proteins like the chloride-bicarbonate anion exchanger (AE2).

System-level physiological consequences include a modified bile composition and an increase in net bile flow.

Official Administration Guidelines

Урсолив (Ursodeoxycholic Acid) is prescribed solely for oral administration and is supplied in multiple dosage forms, including capsules, scored tablets, and oral suspension. The core principle of its use revolves around a weight-based dosing strategy, where the total daily dose is calculated according to the patient's body weight in mg/kg to ensure standardized administration. Scored tablets may be broken to achieve the precise weight-adjusted dose for titration purposes.

---

Dosing Patterns and Timing

The specific daily dosage and administration schedule are dependent on the approved clinical scenario. For Primary Biliary Cholangitis (PBC), the typical adult maintenance dose is in the range of 13–16 mg/kg/day, generally administered as two to four divided doses with meals. The requirement to take the medicine with food is an explicit instruction tied to this regimen. In contrast, the protocol for cholesterol gallstone dissolution often utilizes a lower daily dose, approximately 8–12 mg/kg/day, which is usually consolidated into a single dose taken in the evening.

---

Course Duration and Special Populations

Treatment duration varies significantly based on the indication. Therapy for PBC is typically considered long-term or indefinite. However, gallstone dissolution requires a defined, extended course, often lasting six months to two years and continuing for several months after the stones are no longer visible radiologically. Official guidelines also establish distinct, higher mg/kg doses for pediatric patients managing hepatobiliary disorders associated with cystic fibrosis.

Research evidence / Overview of studies for Урсолив

The research base for Ursodeoxycholic Acid (UDCA), the active ingredient in Урсолив, is built primarily on Randomized Controlled Trials (RCTs) and subsequent large-scale Systematic Reviews and Meta-analyses. These studies focus on two main indications. The following overview describes what the research has explored and what is known and unknown, according to official and peer-reviewed sources.

---

Evidence for Use in Primary Biliary Cholangitis (PBC)

The research exploring the compound’s evaluation for Primary Biliary Cholangitis (PBC) has used controlled trials to understand its role. These studies tracked outcomes related to functional imbalance within the liver, focusing heavily on measurements related to liver health. Research has explored the evaluation in adult patients across various stages of the condition.

Studies reported measurements related to key liver enzyme markers, such as alkaline phosphatase (ALP) and bilirubin, in many of the observed patient populations. Changes in these blood markers were tracked as an endpoint relevant to disease progression in the study design. Furthermore, research has tracked patients over defined time intervals to evaluate outcomes such as transplant-free survival (a long-term endpoint monitored in studies). Findings have been mixed regarding the long-term transplant-free survival for all patients, and the evidence base also currently lacks consistent data to characterize the long-term prognosis for patients who do not show a biochemical change (non-responders).

Study Endpoints and Measured Outcomes

Research on PBC has focused on outcomes that reflect systemic or functional imbalance. Beyond blood tests, the studies also monitored functional measures like the time to clinical events. Follow-up durations in the primary RCTs ranged from two to four years, but subsequent analyses have helped contextualize how patients were observed for up to 10 or more years.

---

Evidence for Use in Cholesterol Gallstone Dissolution

Research has explored how the compound performs in RCTs regarding the dissolution of cholesterol gallstones. These studies monitored the rate of complete gallstone dissolution, typically confirmed using imaging. The research focused on specific populations of adults who had small to medium-sized gallstones that were non-calcified (radiolucent) and had a functioning gallbladder.

Studies reported that the process of dissolution was observed to be slow and often required monitoring for many months or years. Research reported that dissolution was not observed in cases involving calcified gallstones or when the gallbladder was not functioning. Furthermore, research explored and reported that patterns in the data describe a frequent rate of gallstone recurrence.

Common questions about Урсолив (FAQ)

---

Q: How long does it take to see the effect of Ursoliv?

Studies and official documents describe that the active substance reaches steady-state concentrations for conditions like Primary Biliary Cholangitis (PBC) in about three weeks. For gallstone dissolution, evidence indicates that an initial measurable response may be observed after 3 to 6 months of continuous treatment.

Q: Can Ursoliv cause nausea or stomach upset?

Official product information indicates that side effects primarily affect the digestive system. Common adverse reactions reported include diarrhea, pasty stools, abdominal pain, nausea, and general indigestion (dyspepsia).

Q: Can I take Ursoliv if I have chronic gastritis?

Regulatory information states that the medication is contraindicated in patients who have active peptic ulcers or inflammatory diseases affecting the small intestine or colon. This restriction is related to its potential effects on the gastrointestinal lining.

Q: Why is Ursoliv sometimes prescribed for cirrhosis?

The medication is officially approved for the treatment of Primary Biliary Cholangitis (PBC), a condition that can progress to cirrhosis. Evidence indicates that long-term use in patients with PBC is associated with a lower rate of progression to liver cirrhosis.

Q: Does Ursoliv affect general blood tests?

Official safety profiles list the requirement to monitor liver enzyme levels. Additionally, common changes reported in blood tests include leukopenia (a reduction in white blood cell count) and thrombocytopenia (a reduction in platelet count).

Q: Are there official side effects related to the skin?

Yes, the regulatory safety profile does list dermatological side effects. Common reactions include skin rash and alopecia (hair loss). Very rare reactions, such as urticaria (hives), have also been reported.

Q: How quickly is Ursoliv eliminated from the body?

According to official pharmacological data, once the medication is stopped, the concentration of the active substance in bile declines exponentially. It falls to approximately 5% to 10% of its therapeutic level in about one week.

Q: Do I need to follow a special diet while taking Ursoliv?

Official regulatory documents define the conditions of use, stating that administration is typically recommended with meals. The prescribing information does not mandate adherence to a specific restrictive diet.

Q: Can Ursoliv affect sleep?

Yes, insomnia, which is difficulty falling or staying asleep, has been reported as a common side effect in clinical trials of the medication.

Q: Why is Ursoliv often prescribed during pregnancy?

Official safety information clearly states that the medication is generally not recommended for use during pregnancy. For women of childbearing potential, the use of effective non-hormonal contraception is a regulatory requirement during treatment.

Q: How can I tell if Ursoliv has started working?

The action of the medication is monitored objectively by requiring periodic blood tests to track liver function parameters. For gallstone dissolution, treatment progress is confirmed by imaging the gallbladder (such as X-ray or ultrasound) after several months.

Q: Can Ursoliv cause an allergic reaction?

The medication is contraindicated if there is a known hypersensitivity (allergy) to the active substance or any non-active ingredients. Allergic reactions, including rash, hives, and angioedema, have been noted in post-marketing surveillance reports.

Q: Why is Ursoliv sometimes considered the 'gold standard' for gallstone disease?

The active ingredient is a treatment whose use is supported by extensive long-term randomized controlled trial data showing established biochemical and histological benefits in patients with Primary Biliary Cholangitis (PBC).

Q: Are there restrictions for taking Ursoliv in the elderly?

Official regulatory documents define the standard dosage for both 'Adults and Elderly.' There are typically no specific dose restrictions or safety warnings listed based solely on advanced age.

Q: Does Ursoliv affect blood pressure?

The main regulatory safety summaries do not commonly report adverse events related to blood pressure, such as hypertension (high blood pressure) or hypotension (low blood pressure).

Q: Can I take Ursoliv if my gallbladder has been removed?

The medication is approved for Primary Biliary Cholangitis (PBC), a condition where the function of the gallbladder is not essential for treatment. Furthermore, it is also indicated for the prevention of gallstone formation in certain post-operative settings.

Q: How does Ursoliv help with bile stasis in pregnant women?

Official safety information clearly states that the medication is generally not recommended for use during pregnancy. For women of childbearing potential, the use of effective non-hormonal contraception is a regulatory requirement during treatment.

Q: Can Ursoliv be taken to prevent liver disease?

The medication is officially indicated for the prevention of gallstone formation in specific populations, such as obese patients undergoing rapid weight loss. General prevention of liver disease is not listed as an approved use.

Q: Does Ursoliv contain components that may cause intolerance (e.g., lactose)?

Depending on the specific formulation and manufacturer, the composition may include non-active ingredients (excipients) such as lactose, maize starch, or gelatin.

Q: How is Ursoliv used to treat biliary reflux gastritis?

The medication is officially approved for treating Primary Biliary Cholangitis (PBC) and dissolving cholesterol gallstones. Treatment for biliary reflux gastritis is not listed as an official regulatory indication.

Q: Is it true that Ursoliv can be prescribed after gallbladder surgery?

The medication is officially indicated for the prevention of gallstone formation in specific populations, such as obese patients undergoing rapid weight loss. This treatment protocol is often initiated in a post-operative setting.

Q: Does Ursoliv affect the ability to drive?

The official safety profile lists possible side effects such as headache and dizziness which may affect ability. Individuals should be aware of this potential when operating machinery.

Official Storage and Disposal Requirements

Storage and handling for Ursodeoxycholic Acid (Урсолив) are defined by specific regulatory requirements to maintain product stability and safety. The product must be stored below a specified temperature, typically either 25 C or 30 C, depending on the specific formulation and regulatory label.

Storage Conditions

Requirement	Official Regulatory Mandate
Temperature	Store below 25 C or not above 30 C.
Protection	Must be protected from light and moisture and kept in the original container.
Child Safety	Store strictly out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be handled and disposed of in accordance with local regulatory requirements. Official instructions caution against discarding the medicine via wastewater or household waste to protect the environment. Disposal should typically be managed through a pharmacy or designated collection site.